Faeth Therapeutics (FTH) investor relations material

Executive summary

• Completed acquisitions of Faeth Therapeutics and Sensei Biotherapeutics in February 2026, shifting focus to multi-node inhibition therapies for cancer and securing $200 million in PIPE financing.

• Changed company name and began trading under a new ticker symbol in June 2026.

• Advanced lead program PIKTOR, with Phase 2 for endometrial cancer and Phase 1b/2 for breast cancer; topline data expected by year-end 2026.

• Strengthened leadership team and board with new CEO, CFO, and former FDA Commissioner.

• Net loss increased significantly due to acquisition-related expenses and integration costs.

Financial highlights

• Net loss for six months ended June 30, 2026 was $186.2 million, up from $11.8 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $186.4 million as of June 30, 2026, up from $21.2 million at December 31, 2025.

• Operating expenses rose to $189.0 million for the six months, driven by $133.0 million in acquired in-process R&D and higher R&D and G&A costs.

• Stock-based compensation expense was $17.4 million for the six months, up from $0.7 million year-over-year.

• Weighted-average shares outstanding for six months ended June 30, 2026: 3,481,149; for Q2 2026: 5,643,222.

Outlook and guidance

• Cash position expected to fund operations through topline data from ongoing Phase 2 and Phase 1b/2 PIKTOR trials.

• Topline results from Phase 2 PIK-201 trial in endometrial cancer expected by year-end 2026; initial safety and efficacy data from Phase 1b/2 PIK-101 breast cancer trial anticipated in 2027.

• Anticipates lower R&D and G&A expenses in future periods as non-recurring acquisition costs subside, but ongoing expenses will remain higher than pre-acquisition levels.

• Additional financing will be needed to support long-term strategy and commercialization efforts.